Progress in human tumour immunology and immunotherapy - PubMed (original) (raw)
Review
. 2001 May 17;411(6835):380-4.
doi: 10.1038/35077246.
Affiliations
- PMID: 11357146
- DOI: 10.1038/35077246
Review
Progress in human tumour immunology and immunotherapy
S A Rosenberg. Nature. 2001.
Abstract
Studies of the administration of interleukin-2 to patients with metastatic melanoma or kidney cancer have shown that immunological manipulations can mediate the durable regression of metastatic cancer. The molecular identification of cancer antigens has opened new possibilities for the development of effective immunotherapies for patients with cancer. Clinical studies using immunization with peptides derived from cancer antigens have shown that high levels of lymphocytes with anti-tumour activity can be raised in cancer-bearing patients. Highly avid anti-tumour lymphocytes can be isolated from immunized patients and grown in vitro for use in cell-transfer therapies. Current studies are aimed at understanding the mechanisms that enable the cancer to escape from immune attack.
Similar articles
- [Perspectives for tumour immunology: antigen-specific immunotherapy of malignant diseases].
Jäger E, Jäger D, Knuth A. Jäger E, et al. Dtsch Med Wochenschr. 2001 Sep 14;126(37):1011-6. doi: 10.1055/s-2001-17111. Dtsch Med Wochenschr. 2001. PMID: 11555776 Review. German. No abstract available. - Cancer vaccines: preclinical studies and novel strategies.
Palena C, Abrams SI, Schlom J, Hodge JW. Palena C, et al. Adv Cancer Res. 2006;95:115-45. doi: 10.1016/S0065-230X(06)95004-0. Adv Cancer Res. 2006. PMID: 16860657 Review. - The development of new cancer therapies based on the molecular identification of cancer regression antigens.
Rosenberg SA. Rosenberg SA. Cancer J Sci Am. 1995 Jul-Aug;1(2):90-100. Cancer J Sci Am. 1995. PMID: 9166458 Review. - Immunotherapy of melanoma.
Parmiani G, Castelli C, Rivoltini L, Casati C, Tully GA, Novellino L, Patuzzo A, Tosi D, Anichini A, Santinami M. Parmiani G, et al. Semin Cancer Biol. 2003 Dec;13(6):391-400. doi: 10.1016/j.semcancer.2003.09.001. Semin Cancer Biol. 2003. PMID: 15001157 Review. - [Immunotherapy for cancer--modern immunologic strategies in oncology].
Halama N, Zoernig I, Jäger D. Halama N, et al. Dtsch Med Wochenschr. 2008 Oct;133(41):2105-8. doi: 10.1055/s-0028-1091251. Epub 2008 Oct 1. Dtsch Med Wochenschr. 2008. PMID: 18985564 Review. German.
Cited by
- Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2.
Kobayashi N, Hong C, Klinman DM, Shirota H. Kobayashi N, et al. J Immunol. 2013 Feb 15;190(4):1882-9. doi: 10.4049/jimmunol.1201063. Epub 2013 Jan 7. J Immunol. 2013. PMID: 23296706 Free PMC article. - Podoplanin as an Attractive Target of CAR T Cell Therapy.
Waseda M, Kaneko S. Waseda M, et al. Cells. 2020 Aug 26;9(9):1971. doi: 10.3390/cells9091971. Cells. 2020. PMID: 32858947 Free PMC article. Review. - High Systemic Inflammation Response Index (SIRI) Indicates Poor Outcome in Gallbladder Cancer Patients with Surgical Resection: A Single Institution Experience in China.
Sun L, Hu W, Liu M, Chen Y, Jin B, Xu H, Du S, Xu Y, Zhao H, Lu X, Sang X, Zhong S, Yang H, Mao Y. Sun L, et al. Cancer Res Treat. 2020 Oct;52(4):1199-1210. doi: 10.4143/crt.2020.303. Epub 2020 Jul 21. Cancer Res Treat. 2020. PMID: 32718144 Free PMC article. - Dendritic cell infiltration and prognosis of human hepatocellular carcinoma.
Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, Fan J, Tang ZY. Cai XY, et al. J Cancer Res Clin Oncol. 2006 May;132(5):293-301. doi: 10.1007/s00432-006-0075-y. Epub 2006 Jan 19. J Cancer Res Clin Oncol. 2006. PMID: 16421755 - Bcl-2 overexpression enhances tumor-specific T-cell survival.
Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA. Charo J, et al. Cancer Res. 2005 Mar 1;65(5):2001-8. doi: 10.1158/0008-5472.CAN-04-2006. Cancer Res. 2005. PMID: 15753400 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources